Kenneth Blum
Department Physiology and Pharmacology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina
Thomas J.H. Chen
Chang Jung Christian University, Tainan,
Taiwan Republic of China and Changhua Christian Hospital, Changhua, Taiwan
B.W. Downs
Allied Nutraceutical Research, Lederach, Pennsylvania,
Brian Meshkin
Salugen, Inc. San Diego, California
Seth H. Blum
Synapatamine, Inc. San Antonio, Texas,
Manuel Martinez Pons
Brooklyn College, CUNY, New York
Julie F. Mengucci
Euro-American Nutraceuticals, Inc., San Diego
Roger L. Waite
Path Medical Foundation, New York
Vanessa Arcuri
Path Medical Foundation, New York
Michael Varshofsiky
Path Medical Foundation, New York
Eric R. Braverman
Path Medical Foundation, New York
PDF Fulltext XML References
How to cite this article
Kenneth Blum, Thomas J.H. Chen, B.W. Downs, Brian Meshkin, Seth H. Blum, Manuel Martinez Pons, Julie F. Mengucci, Roger L. Waite, Vanessa Arcuri, Michael Varshofsiky and Eric R. Braverman, 2007. Synaptamine (SG8839), An Amino-Acid Enkephalinase Inhibition Nutraceutical Improves Recovery of Alcoholics, A Subtype of Reward Deficiency Syndrome (RDS). Trends in Applied Sciences Research, 2: 132-138.
URL: https://scialert.net/abstract/?doi=tasr.2007.132.138
URL: https://scialert.net/abstract/?doi=tasr.2007.132.138